Core Viewpoint - TG Therapeutics Inc. is recognized as one of the best revenue growth stocks to consider for investment, with analysts maintaining positive ratings despite some adjustments in price targets [1][3]. Group 1: Analyst Ratings and Price Targets - JPMorgan analyst Brian Cheng reduced the price target for TG Therapeutics from $49 to $46 while keeping an Overweight rating on the shares [1]. - H.C. Wainwright analyst Emily Bodnar assigned a Buy rating, highlighting the company's strong commercial momentum and expected clinical catalysts in 2026 [3]. - TD Cowen analyst Tara Bancroft reiterated a Buy rating and set a price target of $50 for TG Therapeutics [3]. Group 2: Clinical Developments - TG Therapeutics presented trial results for its Briumvi treatment for relapsing multiple sclerosis at a medical forum in San Diego on February 6 [3]. - The anticipated clinical catalysts include results for consolidated IV dosing and a self-administered subcutaneous formulation for Briumvi, which could enhance its market share against competitors [3].

Core Insights - TG Therapeutics presented data on BRIUMVI® (ublituximab-xiiy) at the ACTRIMS annual forum, focusing on its clinical applications and real-world study results [1][2]. Company Overview - TG Therapeutics is a biopharmaceutical company dedicated to developing treatments for B-cell diseases, with BRIUMVI approved for treating adult patients with relapsing forms of multiple sclerosis (RMS) [29]. Clinical Studies - The ENABLE study evaluates real-world infusion experiences of patients with RMS on BRIUMVI, showcasing the company's commitment to advancing clinical understanding [2]. - The ULTIMATE I & II trials are Phase 3 studies involving 1,094 patients across 10 countries, comparing BRIUMVI to teriflunomide over 96 weeks [4]. Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed to enhance B-cell depletion efficiency through glycoengineering [5][6]. - It is indicated for various forms of RMS, including clinically isolated syndrome and active secondary progressive disease [7]. Safety and Efficacy Data - In clinical trials, BRIUMVI showed a 56% overall infection rate compared to 54% for teriflunomide, with serious infections at 5% versus 3% [10]. - Infusion reactions occurred in 48% of patients receiving BRIUMVI, with serious reactions in 0.6% [8]. Market Context - Approximately 1 million people in the U.S. are living with MS, with 85% initially diagnosed with relapsing-remitting MS [28].

Core Viewpoint - The article aims to provide informational content regarding investment opportunities and risks, emphasizing the importance of independent research and verification by readers [2][3]. Group 1: Company Analysis - The article does not provide specific details about any particular company or its financial performance, focusing instead on general investment advice [2][3]. Group 2: Industry Insights - There are no specific insights or analyses related to any industry mentioned in the article, as it primarily serves as a general informational piece [2][3].

Core Viewpoint - The article aims to provide informational content regarding investment opportunities and risks, emphasizing the importance of independent research and verification by readers [2][3]. Group 1: Company Analysis - The article does not provide specific details about any particular company or its financial performance, focusing instead on general investment advice [2][3]. Group 2: Industry Insights - There are no specific insights or analyses related to any industry mentioned in the article, as it primarily serves as a general informational piece [2][3].

Core Insights - TG Therapeutics is focused on developing treatments for B-cell diseases, with its flagship product BRIUMVI targeting relapsing multiple sclerosis (RMS) [1] Financial Performance - Goldman Sachs updated its rating for TG Therapeutics to Neutral, maintaining a hold recommendation, with the stock price at $29.54 and a raised price target from $37 to $39 [2][6] - TG Therapeutics projects FY25 revenue to reach approximately $616 million, an 87% increase from $329 million in FY24, and anticipates FY26 revenue between $875 million and $900 million [3][6] - BRIUMVI is expected to contribute around $594 million in product revenue for FY25, with FY26 projections ranging from $825 million to $850 million [4][6] Market Position - Despite a 7.7% decline in shares over the past year, TG Therapeutics remains optimistic about long-term revenue growth driven by BRIUMVI's commercial performance and market share capture [5]

Core Insights - TG Therapeutics (TGTX) shares increased nearly 7% in after-hours trading after the release of preliminary fourth-quarter and full-year 2025 results that exceeded expectations [1] - The company provided optimistic guidance for 2026, highlighting key anticipated milestones related to Briumvi label expansion studies and other pipeline candidates [1] Financial Performance - TG Therapeutics expects total global revenues of approximately $616 million for full-year 2025, surpassing the previous guidance of $600 million and the Zacks Consensus Estimate of $604 million [3] - Briumvi U.S. net product revenues are projected to be around $182 million for the fourth quarter of 2025 [3] - For full-year 2025, Briumvi net product sales are expected to be approximately $594 million in the United States, exceeding the November guidance of around $585 million [4] 2026 Outlook & Pipeline Goals - TGTX anticipates 2026 revenues in the range of $875 million to $900 million, including $825 million to $850 million from U.S. Briumvi sales, indicating potential double-digit year-over-year growth compared to expected 2025 figures [7][8] - The company expects operating expenses of around $350 million for the full year 2026 [8] - Key milestones for 2026 include the announcement of pivotal topline data from the ENHANCE study, which aims to consolidate Briumvi infusions, and results from the subcutaneous Briumvi formulation [9][10] - TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T-cell therapy, with preliminary phase I data expected in the second half of 2026 [11]

Core Insights - U.S. stocks experienced a decline, with the Nasdaq Composite dropping over 200 points on Wednesday [1] - TG Therapeutics Inc reported preliminary total global revenue for fiscal year 2025 of approximately $616 million, leading to a significant increase in its stock price [2] Company Performance - TG Therapeutics reported U.S. net product revenue for BRIUMVI of approximately $182 million for Q4 and $594 million for the full year, with these figures being unaudited [2] - TG Therapeutics shares surged by 11.6% to $31.10 following the revenue announcement [2] Other Notable Stock Movements - Rich Sparkle Holdings Ltd shares increased by 13.5% to $95.31 [3] - Cerus Corp gained 12.7% to $2.84 [3] - Clover Health Investments Corp saw an 11.2% rise to $2.82, driven by year-over-year membership growth in its Medicare Advantage PPO plans [3] - Highpeak Energy Inc shares rose by 8.3% to $5.07 [3] - Nutrien Ltd gained 7% to $65.62 after an upgrade from Morgan Stanley analyst Vincent Sinisi, with a price target increase from $70 to $77 [3]

Market Overview - U.S. stock futures declined on Wednesday following a lower close on Tuesday, with major benchmark indices showing a downward trend [1] - The Consumer Price Index (CPI) rose 2.7% year over year in December, matching previous readings and economists' estimates, while core CPI was slightly below expectations at 2.6% [1] Economic Indicators - The 10-year Treasury bond yielded 4.17%, and the two-year bond yielded 3.52%, indicating investor sentiment towards interest rates [2] - The CME Group's FedWatch tool indicates a 97.2% likelihood of the Federal Reserve maintaining current interest rates in January [2] Stock Performance - Major indices showed the following performances: Dow Jones -0.15%, S&P 500 -0.16%, Nasdaq 100 -0.16%, Russell 2000 +0.14% [3] - SPDR S&P 500 ETF Trust (NYSE:SPY) was down 0.15% at $692.73, while Invesco QQQ Trust ETF (NASDAQ:QQQ) declined 0.20% to $625.00 in premarket trading [3] Company Focus - Wells Fargo & Co. (NYSE:WFC) was down 0.81% in premarket trading, with expected quarterly earnings of $1.67 per share on revenue of $21.65 billion [7] - BP PLC (NYSE:BP) dropped 1.84% after announcing potential writedowns of up to $5 billion in its energy transition businesses [7] - WeRide Inc. ADR (NASDAQ:WRD) rose 1.59% after launching the Robotaxi Mini Program "WeRide Go" on Tencent WeChat [7] Analyst Insights - Professor Jeremy Siegel anticipates a strong 2026 driven by productivity growth, with a surprising fourth-quarter GDP growth estimate of 5.4% [10] - Siegel suggests a shift in stock market leadership away from mega-cap technology stocks, predicting double-digit returns from small-cap stocks and non-tech cyclicals [11] Upcoming Economic Data - Delayed reports on U.S. retail sales and producer price index are scheduled for release at 8:30 a.m. ET [14] - Additional economic data, including business inventories and existing home sales, will be released at 10:00 a.m. ET [14] Commodities and Global Markets - Crude oil futures fell by 0.98% to around $60.57 per barrel, while gold prices rose by 0.93% to approximately $4,629.12 per ounce [16] - Bitcoin traded 3.32% higher at $94,969.36 per coin [16] Global Market Performance - Asian markets closed mixed, with India's Nifty 50 and China's CSI 300 indices falling, while Australia's ASX 200, Japan's Nikkei 225, Hong Kong's Hang Seng, and South Korea's Kospi indices rose [17]

Core Viewpoint - U.S. stock futures are trading lower, with several companies expected to report quarterly earnings, drawing investor attention [1] Company Earnings Expectations - Bank of America Corp (NYSE:BAC) is anticipated to report quarterly earnings of 96 cents per share on revenue of $27.87 billion, with shares slipping 0.1% to $54.51 in after-hours trading [1] - Citigroup Inc (NYSE:C) is expected to post quarterly earnings of $1.68 per share on revenue of $20.53 billion, with shares falling 0.1% to $116.15 in after-hours trading [1] - Wells Fargo & Co (NYSE:WFC) is projected to report quarterly earnings of $1.67 per share on revenue of $21.65 billion, with shares decreasing 0.2% to $93.38 in after-hours trading [1] Company Updates - TG Therapeutics, Inc. (NASDAQ:TGTX) provided preliminary fourth quarter revenue estimates, expecting U.S. net product revenue of approximately $182 million for Q4 and $594 million for the full year of 2025, with total global revenue for 2025 expected to be around $616 million [1] - Gelteq Ltd. (NASDAQ:GELS) reported positive preclinical results for its cannabinoid oral gel delivery platform, leading to a significant share price increase of 69.3% to $1.41 in after-hours trading [1]

Corporate Updates - China SXT Pharmaceuticals, Inc. (SXTC) surged 17.40% to $0.12 after announcing a registered direct offering valued at about $10 million, selling 66,666,666 Class A ordinary shares at $0.15 per share, strengthening its balance sheet and fueling investor optimism [2] - Rapid Micro Biosystems, Inc. (RPID) advanced 8.55% to $3.30 following the release of preliminary unaudited fourth-quarter and full-year 2025 revenue results, sparking a positive reaction in extended trading [3] - TG Therapeutics, Inc. (TGTX) gained 6.99% to $29.82 after announcing preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for the fourth quarter and full year 2025, along with 2026 financial guidance and development milestones [4] - argenx SE (ARGX) rose 2.00% to $826.72 after the FDA accepted for priority review a supplemental Biologics License Application for VYVGART, with a PDUFA target action date of May 10, 2026, indicating potential for expanded indications [5] - Clene Inc. (CLNN) edged higher by 0.98% to $5.15 after announcing an in-person Type C Meeting with the FDA, representing an important step in advancing its pipeline [6] Market Reactions - Cosmos Health Inc. (COSM) climbed 6.09% to $0.4961 despite no company-specific news, highlighting speculative interest and momentum trading in the micro-cap healthcare space [3] - Entera Bio Ltd. (ENTX) gained 4.11% to $1.52 in after-hours trading, reflecting investor activity around small-cap biotech names despite no new corporate updates [7]